

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re U.S. Patent Application of

Wakabayashi *et al.*

Application Number: 10/038,717

Filed: January 8, 2002

For: A Method of Analysis of DNA Sequence

Honorable Assistant Commissioner  
for Patents  
Washington, D.C. 20231

LETTER

Sir:

The below-identified communications are submitted in the above-captioned application or proceeding:

<input type="checkbox"/>	Priority Documents ()	
<input type="checkbox"/>	Request for Priority	(X) Sequence Listing Statement
<input checked="" type="checkbox"/>	Response and Amendment	(X) Sequence Listing Data and Diskette0.0

☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication, including fees under 37 C.F.R. § 1.16 and 1.17 or credit any overpayment to Deposit Account Number 08-1480. A duplicate copy of this sheet is attached.

Respectfully submitted,

Stanley P. Fisher  
Registration Number 24,344

REED SMITH HAZEL & THOMAS LLP

3110 Fairview Park Drive  
Suite 1400  
Falls Church, Virginia 22042  
(703) 641-4200

JUAN CARLOS A. MARQUEZ  
Registration No. 34,072


March 7, 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov


APPLICATION NUMBER	FILED/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/038,717	MAR 08/2002	Yuki Wakabayashi	NITT.0052



Stanley P. Fisher  
Reed Smith Hazel & Thomas  
Suite 1400  
3110 Fairview Park Drive  
Falls Church, VA 22042-4503

CONFIRMATION NO. 8912

## FORMALITIES LETTER



\*OC000000007478511\*

Date Mailed: 02/14/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202  
PART 1 - ATTORNEY/APPLICANT COPY